Targeting A Common Contributor To Severe Asthma
Summary: This webinar will provide an overview of severe eosinophilic asthma and a biologic treatment option. The definition of severe asthma will be reviewed along with the features of “uncontrolled” asthma. The webinar will discuss the proportion of patients with eosinophilic asthma and will highlight key clinical indicators of eosinophilic asthma. The session will highlight a biologic treatment option for severe asthma and will address its indication, pharmacodynamics, pharmacokinetics, formulation, dosing and administration. Clinical efficacy and safety of the biologic treatment option will be discussed along with patient counseling information.
Learning Objectives: Attendees will gain an appreciation for severe asthma and develop an understanding of a biologic treatment option.
Date: Wednesday, March 31, 11:30 AM-12:30 PM EST
Presenter: Mark A. Della Paolera, RPh, PharmD, BCACP
Mark Della Paolera is a pharmacist and Respiratory Medical Science Liaison with AstraZeneca in the Southwest. Mark has been a pharmacist for 23 years and brings a diverse pharmacy background having worked in independent, retail, hospital, and family practice settings. Mark served as a professor at Pacific University School of Pharmacy for almost a decade teaching pulmonary and allergy courses while maintaining an ambulatory care practice site. Mark received his Bachelor’s in Pharmacy from Oregon State University in 1998. After practicing for 5 years, he decided to continue his education through an external program for working adults with the University of Washington where he obtained his Doctorate in Pharmacy in 2008. Mark lives in Phoenix, Arizona and has a passion for patient care, interdisciplinary collaborations, and he is also a Board Certified Ambulatory Care Pharmacist.
Target Audience: Clinical Care Medical Physicians and related healthcare professionals involved in the care of people with asthma.
This webinar is sponsored by: